ライフサイエンスコーパス: tumor necrosis factor receptor

1 sepsis and may result in reduced shedding of tumor necrosis factor receptors.

2 ntly assembles as a trimer, similar to other tumor necrosis factor receptors.

3 0 (1.35), fatty acid-binding protein (1.33), tumor necrosis factor receptor 1 (2.29), and TNF-related

4 -1 receptor antagonist (sIL-1ra) and soluble tumor necrosis factor receptor 1 (sTNF-R1).

5 ects on fibrin accumulation were observed in tumor necrosis factor receptor 1 (TNFR-1)(-/-) mice or i

6 Tumor necrosis factor receptor 1 (TNFR1) activation in h

7 ifically reduced expression of mRNA encoding tumor necrosis factor receptor 1 (TNFR1) as well as TNFR

8 lpha (MIP-1alpha), IL-1 receptor (IL-1R), or tumor necrosis factor receptor 1 (TNFR1) by the use of t

9 Stimulation of tumor necrosis factor receptor 1 (TNFR1) can initiate se

10 Activation of the tumor necrosis factor receptor 1 (TNFR1) death receptor

11 We examined the role of tumor necrosis factor receptor 1 (TNFR1) in inflammation

12 We hypothesized that tumor necrosis factor receptor 1 (TNFR1) levels are asso

13 ptor (TCR) or from a death receptor, such as tumor necrosis factor receptor 1 (TNFR1) or Fas.

14 Ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1) provides negati

15 e that TRADD serves an important function in tumor necrosis factor receptor 1 (TNFR1) signaling by or

16 e 1 (RIPK1) is an important component of the tumor necrosis factor receptor 1 (TNFR1) signaling pathw

17 e signaling and cell death pathways, notably tumor necrosis factor receptor 1 (TNFR1) signaling.

18 strong promoter of liver regeneration, while tumor necrosis factor receptor 1 (TNFR1) was the most si

19 tor alpha (TGFalpha), syndecan-1 (SDC1), and tumor necrosis factor receptor 1 (TNFR1), are shed from

20 TNF, acting through p55 tumor necrosis factor receptor 1 (TNFR1), contributes to

21 c-IAP1 and c-IAP2 are recruited to tumor necrosis factor receptor 1 (TNFR1)-associated comp

22 g similarities with the pathway of mammalian tumor necrosis factor receptor 1 (TNFR1).

23 current fibrosis were absent in mice lacking tumor necrosis factor receptor 1 (TNFR1).

24 ry response syndrome [SIRS]) and laboratory (tumor necrosis factor receptor 1 [TNF-R1], high-sensitiv

25 ng enzyme expression and catalytic activity, tumor necrosis factor receptor 1 and 2 expression, and s

26 rticles, acts as a negative regulator of the tumor necrosis factor receptor 1 and caspase pathways an

27 bjects tended to have higher plasma IL-6 and tumor necrosis factor receptor 1 and lower insulin-like

28 We have reported that E6 binds to tumor necrosis factor receptor 1 and to Fas-associated d

29 uted to a lipid-raft-localized enrichment of tumor necrosis factor receptor 1 in a cholesterol-depend

30 ia TPL-2, including Toll-like receptor 4 and tumor necrosis factor receptor 1 in macrophages, and CD4

31 contrast, tumor necrosis factor knockout and tumor necrosis factor receptor 1 knockout FPs exhibited

32 level, kynurenine/tryptophan ratio, soluble tumor necrosis factor receptor 1 level, high-sensitivity

33 reactive peptide, interleukin-8, and soluble tumor necrosis factor receptor 1 were most different bet

34 TNFR1 (tumor necrosis factor receptor 1) localizes to caveolae

35 Tumor necrosis factor receptor 1, E-selectin, hK11, tumo

36 d nonfrail subjects, we measured serum IL-6, tumor necrosis factor receptor 1, insulin-like growth fa

37 bfamily of cell surface molecules related to tumor necrosis factor receptor 1, is not exclusively the

38 3, TNFRSF25), the closest family relative to tumor necrosis factor receptor 1, promotes CD4(+) T-cell

39 IL)-1 receptor antagonist (sIL-1ra), soluble tumor necrosis factor receptor 1, soluble vascular endot

40 h-inducing signaling complex of both Fas and tumor necrosis factor receptor 1.

41 wild-type controls, both CD40-deficient and tumor necrosis factor receptor 1/2 (TNFR1/2)-deficient m

42 tudies using mice with germline deletions in tumor necrosis factor receptors 1 and 2 (TNFR1,2(-/-)) o

43 ides, C-reactive protein, interleukin-6, and tumor necrosis factor receptors 1 and 2 and decreased hi

44 lasts, wild type or cells lacking functional tumor necrosis factor receptors 1 and 2 were used to ass

45 tivity involves down-regulating cell-surface tumor necrosis factor receptor-1 (TNFR1) and thus, inhib

46 ree-variable model of IL-8, bicarbonate, and tumor necrosis factor receptor-1 accurately classified t

47 median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, wherea

48 lly, TAK1 functions as a molecular switch in tumor necrosis factor receptor-1 signaling by regulating

49 eer levels and reduced inflammation (soluble tumor necrosis factor receptor-1), coagulation (prothrom

50 of three biomarkers (interleukin-8, soluble tumor necrosis factor receptor-1, and surfactant protein

51 High concentrations of tumor necrosis factor receptor-1, interleukin-8, and reg

52 ietin-1, angiopoietin-2, IL-6, IL-8, soluble tumor necrosis factor receptor-1, soluble vascular cell

53 r antigen, surfactant protein-D, and soluble tumor necrosis factor receptor-1, which are biomarkers o

54 these effects were abolished by ablation of tumor necrosis factor receptor-1.

55 tic biomarkers of GVHD (IL-2 receptor-alpha; tumor necrosis factor receptor-1; hepatocyte growth fact

56 of 4 proteins (interleukin-2-receptor-alpha, tumor-necrosis-factor-receptor-1, interleukin-8, and hep

57 n (CRP), interleukin (IL)-6, and the soluble tumor necrosis factor receptor 2 (sTNFR-2) in blood samp

58 I], 1.7-4.2; Ptrend = 1.0 x 10(-6)), soluble tumor necrosis factor receptor 2 (sTNFR2; OR, 3.4; 95% C

59 are the result of greater signaling through tumor necrosis factor receptor 2 (TNFR2) and/or interleu

60 ore allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell b

61 Tumor necrosis factor receptor 2 (TNFR2) is known to med

62 ulating CD4+CD25+CD127lo/- and CD4+CD127lo/- tumor necrosis factor receptor 2 (TNFR2)+ Treg cells wer

63 = 4941), interleukin 6 (IL-6, n = 2859), and tumor necrosis factor receptor 2 (TNFR2, n = 2905).

64 Tumor necrosis factor receptor 2 (TNFR2, Tnfrsf1b) regul

65 Wild-type C57Bl/6 mice or tumor necrosis factor receptor 2 knockout mice, either f

66 Three proteins (haptoglobin, tumor necrosis factor receptor 2 or IL-10, and tissue in

67 matory process dominated by markers: soluble tumor necrosis factor receptor 2, soluble interleukin 2

68 n molecule-1, interleukin-6, P-selectin, and tumor necrosis factor receptor-2 (multivariable model R2

69 ular adhesion molecule-1, interleukin-6, and tumor necrosis factor receptor-2 (TNF-R2)].

70 levels of leptin, interleukin-6, and soluble tumor necrosis factor receptor-2, as well as the homeost

71 We have previously shown that TNF-tumor necrosis factor receptor-2/p75 (TNFR2/p75) signali

72 LMP1 acts as a constitutively active tumor necrosis factor receptor and activates multiple fo

73 ssed normal levels of glucocorticoid-induced tumor necrosis factor receptor and cytotoxic T-lymphocyt

74 er, the expression of glucocorticoid-induced tumor necrosis factor receptor and OX40 on CD4+CD25(high

75 ells expressing CD25, glucocorticoid-induced tumor necrosis factor receptor, and cytotoxic T lymphocy

76 cluding Neuropilin 1, glucocorticoid-induced tumor necrosis factor receptor, and cytotoxic T lymphocy

77 n receptors, T-cell and B-cell receptors and tumor necrosis factor receptors, and discuss Pellinos ro

78 Our goal was to identify whether tumor necrosis factor receptor apoptosis-inducing ligand

79 major histocompatibility complex class I and tumor necrosis factor receptor as well as reduced extrac

80 diated by Math-BTB/POZ (for Meprin and TRAF [tumor necrosis factor receptor associated factor] homolo

81 Moreover, we found that the expression of tumor necrosis factor receptor-associated death domain (

82 Uncontrolled activation of tumor necrosis factor receptor-associated factor (TRAF)

83 receptor superfamily member CD40, utilizing tumor necrosis factor receptor-associated factor (TRAF)

84 -1) receptor-associated kinase (IRAK)-2, and tumor necrosis factor receptor-associated factor (TRAF)-

85 Tumor necrosis factor receptor-associated factor (TRAF)2

86 Tumor necrosis factor receptor-associated factor 1 (TRAF

87 ant to chronic inflammation: TRAF1 (encoding tumor necrosis factor receptor-associated factor 1) and

88 We examined the role of tumor necrosis factor receptor-associated factor 2 (Traf

89 IKKepsilon interacts with and phosphorylates tumor necrosis factor receptor-associated factor 2 (TRAF

90 Here we report that tumor necrosis factor receptor-associated factor 2 (TRAF

91 Consistent with its ability to interact with tumor necrosis factor receptor-associated factor 2 (TRAF

92 n ligases in the human genome and identified tumor necrosis factor receptor-associated factor 2 (TRAF

93 on of API2-MALT1 as well as interaction with tumor necrosis factor receptor-associated factor 2 (TRAF

94 at receptor-interacting protein 1 (RIP1) and tumor necrosis factor receptor-associated factor 2 (TRAF

95 The tumor necrosis factor receptor-associated factor 2 (TRAF

96 eus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF

97 through a common scaffolding protein termed tumor necrosis factor receptor-associated factor 2 (TRAF

98 s essential for TLR9-dependent activation of tumor necrosis factor receptor-associated factor 3 (TRAF

99 DUBA bound tumor necrosis factor receptor-associated factor 3 (TRAF

100 Tumor necrosis factor receptor-associated factor 3 (TRAF

101 activation of the downstream effector TRAF3 (tumor necrosis factor receptor-associated factor 3).

102 DLBCL induces recruitment and degradation of tumor necrosis factor receptor-associated factor 3, whic

103 e show that Smurf1 induces ubiquitination of tumor necrosis factor receptor-associated factor 4 (TRAF

104 1 and M2 subsets was critically dependent on tumor necrosis factor receptor-associated factor 6 (TRAF

105 Tumor necrosis factor receptor-associated factor 6 (TRAF

106 Here we unveiled the role of tumor necrosis factor receptor-associated factor 6 (TRAF

107 To study the cell-specific role of tumor necrosis factor receptor-associated factor 6 (TRAF

108 m specifically induces the ubiquitination of tumor necrosis factor receptor-associated factor 6 (TRAF

109 Tumor necrosis factor receptor-associated factor 6 (TRAF

110 Tumor necrosis factor receptor-associated factor 6 (TRAF

111 Tumor necrosis factor receptor-associated factor 6 (TRAF

112 L-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF

113 h receptor interacting protein-2 (RIP2)- and tumor necrosis factor receptor-associated factor 6 (TRAF

114 appaB at the level of (or downstream of) the tumor necrosis factor receptor-associated factor 6 compl

115 d low levels of Cathepsin K, TRAP, RANK, and tumor necrosis factor receptor-associated factor 6 mRNAs

116 interleukin receptor-associated kinase 2 and tumor necrosis factor receptor-associated factor 6 to su

117 Thus, cellular mechanisms that suppress tumor necrosis factor receptor-associated factor 6 ubiqu

118 ling to nuclear factor kappaB by suppressing tumor necrosis factor receptor-associated factor 6 ubiqu

119 s modification of the signaling intermediary tumor necrosis factor receptor-associated factor 6 with

120 ignaling through the ubiquitin ligase TRAF6 (tumor necrosis factor receptor-associated factor 6).

121 binding to, but impaired ubiquitination of, tumor necrosis factor receptor-associated factor 6, a vi

122 icantly enhanced Lys63 polyubiquitination of tumor necrosis factor receptor-associated factor 6, acti

123 n vitro, and this requires IL-17 receptor A, tumor necrosis factor receptor-associated factor 6, and

124 restricting ubiquitylation of the E3 ligase tumor necrosis factor receptor-associated factor 6.

125 ation of IRAK4, and subsequent activation of tumor necrosis factor receptor-associated factor 6.

126 t Asn-234 and Asn-270, as well as one in the tumor necrosis factor receptor-associated factor domain

127 Here, we demonstrate that the TRAF (tumor necrosis factor receptor-associated factor) family

128 e receptors, IL-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor-6, IL8/

129 the common variant D10N, located in the ACT1 tumor necrosis factor receptor-associated factor-interac

130 we report that STP-A interacts with cellular tumor necrosis factor receptor-associated factors (TRAF2

131 smic domain to adaptor proteins, such as the tumor necrosis factor receptor-associated factors (TRAFs

132 The recruitment of tumor necrosis factor receptor-associated factors (TRAFs

133 t (CTAR1) or indirect (CTAR2) recruitment of tumor necrosis factor receptor-associated factors (TRAFs

134 Tumor necrosis factor receptor-associated factors (TRAFs

135 R domains of c-IAP1 and c-IAP2 interact with tumor necrosis factor receptor-associated factors 1 and

136 poptosis 1 and 2 (c-IAP1/2) proteins and the tumor necrosis factor receptor-associated factors 2 and

137 amilial Mediterranean fever, 12 patients had tumor necrosis factor receptor-associated periodic syndr

138 ness to LPS seen in cells from patients with tumor necrosis factor receptor-associated periodic syndr

139 outcomes in the first case of a patient with tumor necrosis factor receptor-associated periodic syndr

140 Tumor necrosis factor receptor-associated periodic syndr

141 Tumor necrosis factor receptor-associated periodic syndr

142 recognized in familial Mediterranean fever, tumor necrosis factor receptor-associated periodic syndr

143 ate the anti-apoptotic and survival protein, tumor necrosis factor receptor-associated protein 1 (Tra

144 croptotic signaling with the adaptor protein tumor necrosis factor receptor-associated protein with d

145 that mitochondrial HSP90 proteins, including tumor necrosis factor receptor-associated protein-1 (TRA

146 at a mitochondria-localized Hsp90 chaperone, tumor necrosis factor receptor-associated protein-1 (TRA

147 aperone complex comprising Hsp60, Hsp90, and tumor necrosis factor receptor-associated protein-1, sel

148 amily C, member 4-associated protein)/TRUSS (tumor necrosis factor receptor-associated ubiquitous sca

149 Studies examining tumor-necrosis factor receptor-associated factors (TRAFs

150 The 55-kDa TNFR1 (type I tumor necrosis factor receptor) can be released to the e

151 train GRI-90 D2L/I4R CrmB and D13L CD30-like tumor necrosis factor receptors, D3L/I3R and C1L ankyrin

152 imilarly, interleukin-6 (IL-6)-deficient and tumor necrosis factor-receptor-deficient mice underwent

153 in 1 (LMP1) is a functional homologue of the tumor necrosis factor receptor family and contributes su

154 th other BH3-only proteins or members of the tumor necrosis factor receptor family in getting rid of

155 The chemokine receptor CCR7 and the tumor necrosis factor receptor family member CD27 define

156 We show that the expression of a tumor necrosis factor receptor family member, death rece

157 CD40, a tumor necrosis factor receptor family member, is express

158 Expression and signaling of CD30, a tumor necrosis factor receptor family member, is up-regu

159 ate signaling by Toll-like receptors (TLRs), tumor necrosis factor receptor family members and cytoki

160 e demonstrate that costimulation through the tumor necrosis factor receptor family molecule OX40, in

161 CD30 (TNFRSF8), a tumor necrosis factor receptor family protein, and CD30

162 pathway activated by Toll-like receptor and tumor necrosis factor receptor family stimulation.

163 CD40, a member of the tumor necrosis factor receptor family, and its ligand, C

164 ch ectodomain of human Fn14, a member of the tumor necrosis factor receptor family, and the IgV domai

165 onal antibody against glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR

166 with an agonist anti-glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR

167 The glucocorticoid-induced tumor necrosis factor receptor family-related protein (G

168 rized gene with structural similarity to the tumor necrosis factor receptor family.

169 CD30 is a member of the tumor necrosis factor receptor family.

170 T-cell signaling via CD137, a member of the tumor necrosis factor-receptor family.

171 Blockade, by either monoclonal antibody or tumor necrosis factor receptor gene knockout, reduced in

172 Ligation between glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand (GI

173 ate the expression of glucocorticoid-induced tumor necrosis factor receptor (GITR) compared with Treg

174 Glucocorticoid-induced tumor necrosis factor receptor (GITR), found constitutiv

175 ss the ligand for the glucocorticoid-induced tumor necrosis factor receptor (GITRL), which was confir

176 Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen

177 dependently of its ligand, the costimulatory tumor necrosis factor receptor herpesvirus entry mediato

178 , plasma interleukin 6 (IL-6) level, soluble tumor necrosis factor receptor I (sTNFR-I) level, sTNFR-

179 Ly6G(hi) myeloid cells failed to upregulate tumor necrosis factor receptor I (TNF-RI) and to produce

180 owth factor receptor ligand amphiregulin and tumor necrosis factor receptor I (TNFRI) from the surfac

181 ll adhesion molecule 1 (VCAM-1), P-selectin, tumor necrosis factor receptor I (TNFRI), and CXCL16, pa

182 in Toll-like receptor 2 (TLR2)-deficient and tumor necrosis factor receptor I (TNFRI)-deficient mice

183 t cell tryptase, histamine, IL-6, IL-10, and tumor necrosis factor receptor I) was also associated wi

184 C5a), cytokines (IL-2, IL-6, IL-10), soluble tumor necrosis factor receptor I, and platelet activatin

185 mor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sT

186 in (r=0.28), interleukin-6 (r=0.22), soluble tumor necrosis factor receptor II (r=0.22), soluble inte

187 for levels of interleukin-6 (IL-6), soluble tumor necrosis factor receptor II (sTNFRII) (as a proxy

188 ntibodies, interleukin-6 (IL-6), and soluble tumor necrosis factor receptor II (sTNFRII).

189 Tumor necrosis factor receptor II (TNFRII) is one of the

190 ios(-) Tregs, which express higher levels of tumor necrosis factor receptor II (TNFRII), was suppress

191 pregnancy or infection, circulating soluble tumor necrosis factor receptor II was highest in infecte

192 y C-reactive protein, interleukin 6, soluble tumor necrosis factor receptor II, soluble intercellular

193 OS-modified CII scFv fused to soluble murine tumor necrosis factor receptor II-Fc fusion protein (mTN

194 ies have proposed that activation of several tumor necrosis factor receptors, including Death Recepto

195 coding the N1347S mutation was attenuated in tumor necrosis factor receptor-induced apoptosis.

196 the up-regulation of glucocorticoid-induced tumor necrosis factor receptor-ligand (TNFsf18) on dendr

197 gh the role of additional factors, including tumor necrosis factor receptor-ligand interactions, has

198 By using BMMs from tumor necrosis factor receptor p55 knockout mice, we als

199 rized of which is the glucocorticoid-induced tumor necrosis factor receptor-related (GITR) protein.

200 Here we show that glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), a

201 play increased CD103, glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), O

202 Itch was essential for the termination of tumor necrosis factor receptor signaling by controlling

203 K13 bypasses the upstream components of the tumor necrosis factor receptor signaling pathway and dir

204 tive regulator of the Toll-like receptor and tumor necrosis factor receptor signaling pathways, was f

205 ell infiltration or proliferation as well as tumor necrosis factor receptor signaling.

206 tigate whether circulating levels of soluble tumor necrosis factor receptors (sTNFR) are predictive o

207 crosis factor-[alpha], type I and II soluble tumor necrosis factor receptors (sTNFR-I and -II), prote

208 the role of neuronally expressed, paralogous tumor necrosis factor receptor super family (TNFRSF) mem

209 protein 6, low-density lipoprotein receptor, tumor necrosis factor receptor super-family 10, growth a

210 factor-inducible 14 (Fn14), a member of the tumor necrosis factor receptor super-family, is induced

211 Using an agonistic tumor necrosis factor-receptor super family (TNFRSF) 25

212 Upon ligand binding, RIPK1 is recruited to tumor necrosis factor receptor superfamily (TNFRSF) and

213 One such gene, tumor necrosis factor receptor superfamily 14 (TNFRSF14)

214 We identify the tumor necrosis factor receptor superfamily 25 (TNFRSF25)

215 4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an indu

216 or-inducible 14 (Fn14), distantly related to tumor necrosis factor receptor superfamily and a recepto

217 OX40 is a member of the tumor necrosis factor receptor superfamily and is a pote

218 Wnt signaling up-regulated a member of the tumor necrosis factor receptor superfamily called TROY.

219 Death receptors are members of the tumor necrosis factor receptor superfamily characterized

220 arying roles that receptors belonging to the tumor necrosis factor receptor superfamily have on thymu

221 Death receptors are members of the tumor necrosis factor receptor superfamily involved in t

222 macrophage scavenger receptor 1 (MSR1), and tumor necrosis factor receptor superfamily member 10b (T

223 -mediated leukemic cell survival depended on tumor necrosis factor receptor superfamily member 13B (T

224 To investigate the effect of mutations in tumor necrosis factor receptor superfamily member 1A (TN

225 with MAbT25 to expand cells that express the tumor necrosis factor receptor superfamily member 25 (TN

226 Expression of tumor necrosis factor receptor superfamily member 9 (TNF

227 lating factor (GM-CSF); lymphotactin (XCL1); tumor necrosis factor receptor superfamily member 9 (TNF

228 acrophage colony-stimulating factor (M-CSF), tumor necrosis factor receptor superfamily member 9, CCL

229 onstitutively active functional mimic of the tumor necrosis factor receptor superfamily member CD40,

230 how that the neurotrophin receptor p75NTR, a tumor necrosis factor receptor superfamily member expres

231 with this, an agonist antibody targeting the tumor necrosis factor receptor superfamily member OX40 (

232 erozygous mutations in the gene encoding the tumor necrosis factor receptor superfamily member TACI a

233 and, herpesvirus entry mediator (HVEM), is a tumor necrosis factor receptor superfamily member.

234 r immunomodulatory antibodies, including the tumor necrosis factor receptor superfamily members GITR

235 cell precursors expressed high levels of the tumor necrosis factor receptor superfamily molecule GITR

236 Death receptors (DRs) are members of the tumor necrosis factor receptor superfamily that possess

237 CD30 is a member of the tumor necrosis factor receptor superfamily whose express

238 ophin receptor (p75(NTR)) is a member of the tumor necrosis factor receptor superfamily with a widesp

239 y receptor for FIV is CD134, a member of the tumor necrosis factor receptor superfamily, and all prim

240 cule for the death receptor subfamily of the tumor necrosis factor receptor superfamily, but it is al

241 s maintained by signaling via members of the tumor necrosis factor receptor superfamily, CD27 and 4-1

242 ncipal viral oncoprotein and a member of the tumor necrosis factor receptor superfamily, is a constit

243 e p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily, is required

244 morphogenetic protein 7, and Tweak receptor (tumor necrosis factor receptor superfamily, member 12A).

245 We validated the activation of TNFRSF6B (tumor necrosis factor receptor superfamily, member 6b),

246 atory molecules of the tumor necrosis factor/tumor necrosis factor receptor superfamily, such as TNF-

247 oinflammatory member of the immunomodulatory tumor necrosis factor receptor superfamily, which has be

248 (DR5) is an apoptosis-inducing member of the tumor necrosis factor receptor superfamily, whose activi

249 own as 4-1BB and TNFRSF9) is a member of the tumor necrosis factor receptor superfamily.

250 cytokine receptors such as those in the TNF (tumor necrosis factor) receptor superfamily, a series of

251 ant differentially expressed genes include a tumor necrosis factor-receptor superfamily member, an in

252 ous triggers, including ligand engagement of tumor necrosis factor receptor (TNF-R) family receptors.

253 rectly binds to a number of receptors of the tumor necrosis factor receptor (TNF-R) superfamily.

254 and their ligands, and tumor necrosis factor-tumor necrosis factor receptor (TNF-TNFR) pairs have pro

255 deletion of GATA3, and mice with deletion of tumor necrosis factor receptor (TNFR) 1 and TNFR2 (TNFR

256 vascular endothelial cell (EC) expression of tumor necrosis factor receptor (TNFR) 2 is induced in si

257 The interaction of the tumor necrosis factor receptor (TNFR) CD27 with its liga

258 model anti-inflammatory agent is the type II tumor necrosis factor receptor (TNFR) decoy receptor.

259 Indeed, CD40, a tumor necrosis factor receptor (TNFR) family member, for

260 particular, agonistic antibodies that target tumor necrosis factor receptor (TNFR) family members hav

261 Tumor necrosis factor receptor (TNFR) family members suc

262 lar, targeting co-stimulatory members of the tumor necrosis factor receptor (TNFR) family with agonis

263 Tumor necrosis factor receptor (TNFR) preligand assembly

264 entivirus receptor 1 (ELR1), a member of the tumor necrosis factor receptor (TNFR) protein family, ha

265 immunostimulatory receptors belonging to the tumor necrosis factor receptor (TNFR) superfamily are em

266 differentiation, and cytokine responses, the tumor necrosis factor receptor (TNFR) superfamily member

267 in in the intrinsic death pathway, or Fas, a tumor necrosis factor receptor (TNFR) superfamily member

268 CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, is ex

269 t membrane protein 1 (LMP1), a member of the tumor necrosis factor receptor (TNFR) superfamily, throu

270 It is a member of the tumor necrosis factor receptor (TNFR) superfamily, whose

271 rther hypothesized that Fas, a member of the tumor necrosis factor receptor (TNFR) superfamily, would

272 cal apoptosis-inducing death receptor in the tumor necrosis factor receptor (TNFR) superfamily.

273 he activation of Toll-like receptor (TLR)-2, tumor necrosis factor receptor (TNFR)-1 and closely rela

274 Tumor necrosis factor receptor (TNFR)-associated factor

275 Tumor necrosis factor receptor (TNFR)-associated factor

276 Tumor necrosis factor receptor (TNFR)-associated factor

277 The signaling adapter protein tumor necrosis factor receptor (TNFR)-associated factor

278 Tumor necrosis factor receptor (TNFR)-associated factor

279 Tumor necrosis factor receptor (TNFR)-associated factors

280 Tumor necrosis factor receptor (TNFR)-associated periodi

281 cell stimulation via glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (G

282 study was initiated to determine whether the tumor necrosis factor receptor (TNFR)1-TNF pathway is in

283 ently, a direct interaction between PGRN and tumor necrosis factor receptors (TNFR I/II) was reported

284 ppaB (NF-kappaB) transcription factor in the tumor necrosis factor-receptor (TNFR) and Toll-like rece

285 motif, IProx, that shares homology with the tumor-necrosis-factor receptor (TNFR)-associated factors

286 crovascular endothelial cells expressing the tumor necrosis factor receptors TNFR1 and TNFR2 with the

287 The type I, 55-kDa tumor necrosis factor receptor (TNFR1) is released from

288 and genomic gains of TNFRSF1B, encoding the tumor necrosis factor receptor TNFR2, in 18% of patients

289 We report that PGRN bound directly to tumor necrosis factor receptors (TNFRs) and disturbed th

290 The family of tumor necrosis factor receptors (TNFRs) and their ligand

291 cted targets, including interleukin-13 and 3 tumor necrosis factor receptors (TNFRs): Fas, FasL, and

292 olecules to mediate signal transduction from Tumor Necrosis Factor Receptor to downstream effector mo

293 6 receptor subunit gp130 (gp130), but not to tumor necrosis factor receptor type 1 (TNFR1), inhibited

294 r necrosis factor-alpha (TNF-alpha), soluble tumor necrosis factor receptor type I (sTNFR-I), and sol

295 actor receptor type I (sTNFR-I), and soluble tumor necrosis factor receptor type II (sTNFR-II) in per

296 -alpha) concentrations and increased soluble tumor necrosis factor receptor type II (sTNFRII) in bron

297 bsets, regulatory T-cell (Treg) frequencies, tumor necrosis factor receptor type II (TNFRII) expressi

298 also displayed reduced shedding of monocyte tumor necrosis factor receptors upon stimulation with li

299 ein, temperature, interleukin 8, and soluble tumor necrosis factor receptor were also reduced (P < 0.

300 Levels of soluble tumor necrosis factor receptors were higher in the prese